VR Logo

Eagle Pharmaceuticals Inc. (EGRX) download report


Healthcare | Drugs & Pharma

Eagle Pharmaceuticals Inc. (EGRX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.

IPO Date: 12-Feb-2014

Founder, Pres, CEO & Director: Mr. Scott L. Tarriff

Chief Financial Officer: Mr. Brian Joseph Cahill

Listing: NASDAQ: EGRX

Country: United States

Headquarters: Woodcliff Lake, NJ

Website: https://www.eagleus.com

Key Facts

Market cap: $466.45 Mln

Revenue (TTM): $246.17 Mln

Earnings (TTM): $35.85 Mln

Cash: $69.52 Mln

Total Debt: $27.63 Mln

Insider's Holding: 12.54%

Liquidity: Low

52 Week range: $33.72 - 58.25

Shares outstanding: 13,214,600

10 Years Aggregate:

  • CFO: $253.22 Mln
  • EBITDA: $188.74 Mln
  • Net Profit: $150.29 Mln

Stock Performance

Time Period Eagle Pharmaceuticals (EGRX) S&P BSE Healthcare S&P Small-Cap 600
YTD-29.71-12.05-8.13
1 month-20.243.3214.13
3 months-16.733.4512.23
1 Year-24.16-11.41-5.78
3 Years-14.3622.0011.43
5 Years-8.4512.479.16
10 Years--12.2011.05
As on 12-Aug-2022
Year Eagle Pharmaceuticals (EGRX) S&P Small-Cap 600 S&P BSE Healthcare
20219.3425.2720.87
2020-22.499.5761.45
201949.1220.86-3.55
2018-24.46-9.70-5.89
2017-32.6711.730.49
2016-10.5224.74-12.88
2015472.06-3.3615.06